

31692-WO-1-ORD_ST25
SEQUENCE LISTING

<110> The Regents of the University of Michigan
Ascenta Therapeutics, Inc.
Sanofi

<120> Spiro-Oxindole MDM2 Antagonists

<130> UM-31692/WO-1/ORD

<150> US 61/451,968
<151> 2011-03-11

<150> US 61/413,094
<151> 2010-11-12

<160> 1

<170> PatentIn version 3.5

<210> 1
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> The residue at this position is linked to 5-Carboxyfluorescein

<220>
<221> MISC_FEATURE
<222> (1)..(2)
<223> The residues at these positions are beta-alanine

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> The residue at this position is alpha-aminoisobutyric acid

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> The residue at this position is phosphotyrosine

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> The residue at this position is 6-Cl-LTrp

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> The residue at this position is 1-amino-cyclopropanecarboxylic acid

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> The residue at this position is linked to NH2

<400> 1

Ala Ala Phe Met Xaa Tyr Trp Glu Xaa Leu Asn
Page 1

1

5

31692-WO-1-ORD_ST25
10